Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | AML treatment: ASH 2020 and beyond

Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses current treatments in acute myeloid leukemia (AML) and what advancements in AML therapies are on the horizon. Venetoclax, a BCL-2 inhibitor, is a major player in the current treatment options, proving highly effective in combination with azacitidine, and acting synergistically with numerous other treatments. Evidence of its combined activity with gilteritinib was presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition. Immunotherapy will likely be a future focus in AML with promising early results from magrolimab trials, the first immunotherapy in AML. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Thomas Cluzeau, MD, PhD, has undertaken clinical research with Aprea (PI GFM APR), Novartis, Alexion, Celgene/BMS, Amgen, Syros, Kartos and Arog; has participated in advisory boards with Celgene, Abbvie, Jazz Pharma, Roche, Novartis and Agios; has fulfilled an educational role with Novartis, Amgen, Sanofi and Astellas; and has attended international congresses with Sanofi, Pfizer, Celgene and Novartis.